Home
Product
Antibody
Biosimilar Antibodies
LILRA4 (daxdilimab Biosimilar) Recombinant Monoclonal Antibody

LILRA4 (daxdilimab Biosimilar) Recombinant Monoclonal Antibody

Code: CSB-RA012936MB1HU

Rate （N/A）
Review （0）

Size:

100ug

100ug500ug1mg5mg10mg50mg100mg200mg

US$199

Quantity:

Species Reactivity: Human

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

P59901

Alternative Names

CD85 antigen-like family member G antibody; CD85g antibody; ILT-7 antibody; ILT7 antibody; Immunoglobulin like transcript 7 antibody; Immunoglobulin-like transcript 7 antibody; Leukocyte immunoglobulin-like receptor subfamily A member 4 antibody; LILRA4 antibody; LIRA4_HUMAN antibody; MGC129597 antibody; MGC129598 antibody

Species Reactivity

Human

Immunogen

Recombinant Human LILRA4 protein

Conjugate

Non-conjugated

Clonality

Monoclonal

Buffer

0.01M PBS，pH7.4

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Notes

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.

Lead Time

In stock
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Concentration

It differs from different batches. Please contact us to confirm it.

Usage

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Datasheet & COA

Antibody FAQs

Description

This recombinant monoclonal antibody is developed as a research-grade biosimilar to daxdilimab, targeting LILRA4 (Leukocyte Immunoglobulin-Like Receptor Subfamily A Member 4), also known as ILT7 or CD85g. LILRA4 is exclusively expressed on plasmacytoid dendritic cells (pDCs), a specialized immune cell subset that plays a critical role in antiviral immunity and type I interferon production. This receptor functions as an inhibitory regulator, modulating pDC activation and preventing excessive inflammatory responses. Aberrant LILRA4-expressing pDC activity has been implicated in various autoimmune diseases, including systemic lupus erythematosus, psoriasis, and other inflammatory conditions where type I interferon signatures contribute to pathogenesis.

Daxdilimab represents a therapeutic antibody designed to deplete or modulate pDCs through LILRA4 targeting, currently under investigation for autoimmune disorders. This biosimilar antibody provides researchers with a valuable tool for investigating pDC biology, LILRA4-mediated signaling pathways, and the role of type I interferons in disease models. It supports studies exploring immune regulation mechanisms and potential therapeutic interventions in interferon-driven pathologies.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Functions coreceptor to limit the innate immune responses to viral infections; signaling occurs via FCER1G. Down-regulates the production of IFNA1, IFNA2, IFNA4, IFNB1 and TNF by plasmacytoid dendritic cells that have been exposed to influenza virus or cytidine-phosphate-guanosine (CpG) dinucleotides, indicating it functions as negative regulator of TLR7 and TLR9 signaling cascades. Down-regulates interferon production in response to interaction with BST2 on HIV-1 infected cells. Activates a signaling cascade in complex with FCER1G that results in phosphorylation of Src family and Syk kinases and thereby triggers mobilization of intracellular Ca(2+). Does not interfere with the differentiation of plasmacytoid dendritic cells into antigen-presenting cells.

Gene References into Functions

Crosslinked ILT7 favours the differentiation of immature plasmacytoid dendritic cells into antigen-presenting cells rather than IPC. PMID:24586760
ILT7 may exert its immunomodulatory activity only on immature circulating plasmacytoid dendritic cells (pDCs), providing a basic homeostatic mechanism rather than negative feedback control on activated pDCs. PMID:23401591
Intracellular expression of the TCL1 as well as membrane and intracellular expression of ILT7 in plasmacytoid dendritic cell leukemia (pDCL) samples and 61 non-pDC acute leukemia samples, were tested. PMID:22674796
the expression of immunoglobulin-like transcript 7, in plasmacytoid dendritic cells PMID:12384430
ILT7 protein associates with the signal adapter protein Fc epsilonRI gamma to form a receptor complex in dendritic cells. PMID:16735691
key regulator of human pDC function and interferon type I production. PMID:18048391
Data show that BST2 directly binds to purified ILT7, initiates signaling via the ILT7-FcepsilonRIgamma complex, and regulates TLR7/9 responses in plasmacytoid dendritic cells. PMID:19564354